Evidence map›Paper›PMID 38736956›Full record

ReviewMediterranean journal of rheumatology2024

State of the Art Review on the Treatment of Psoriatic Disease.

Eleftherios Pelechas, Evripidis Kaltsonoudis, Michalis P Migkos, Nikolaos Koletsos, Panagiota G Karagianni, Alexandros A Drosos, Paraskevi V Voulgari

Abstract readReview
In one paragraph

Review in Mediterranean journal of rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Psoriatic Arthritis: Developments in 2025.Mediterranean journal of rheumatology · 2026
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Eleftherios PelechasDepartment of Rheumatology, Medical School, University of Ioannina, Ioannina, Greece.
Evripidis KaltsonoudisDepartment of Rheumatology, Medical School, University of Ioannina, Ioannina, Greece.
Michalis P MigkosDepartment of Rheumatology, Medical School, University of Ioannina, Ioannina, Greece.
Nikolaos KoletsosDepartment of Rheumatology, Medical School, University of Ioannina, Ioannina, Greece.
Panagiota G KaragianniDepartment of Microbiology, Medical School, University of Ioannina, Ioannina, Greece.
Alexandros A DrososDepartment of Rheumatology, Medical School, University of Ioannina, Ioannina, Greece.
Paraskevi V VoulgariDepartment of Rheumatology, Medical School, University of Ioannina, Ioannina, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Psoriasis is an inflammatory skin disease that in some cases is accompanied by systemic manifestations. Given the varied clinical manifestations, the term psoriatic disease probably better reflects the clinical picture of these patients. Literature review: In most cases, the skin lesions precede joint involvement as well as other potentially involved organs such as the intestine and the eye. Various immune-mediated cellular pathways such as that of TNFα, IL-23, IL-17 as well as other cytokines are involved in the pathophysiology of the psoriatic disease. Future insights: A better understanding of the way they interfere with our immune system has led to remarkably better disease control and outcomes. This review aims to highlight the newest treatments for psoriatic disease, which are expected to significantly reduce unmet needs and treatment gaps.

Indexed as

IL inhibitorsJAK inhibitorspsoriasispsoriatic arthritispsoriatic diseaseTYK inhibitors

Identifiers

PMID38736956
PMCPMC11082764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.